MedPath

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer.

Phase 3
Conditions
Advanced (nonresectable/recurrent) gastric cancer
Registration Number
JPRN-jRCT1080220046
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with nonresectable or recurrent gastric cancer which is histologically confirmed adenocarcinoma.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survival and adverse events
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath